youtube_live
Q3 2026 earnings • released • EPS beat +6.06%
See resultschevron_right
CMPS:NASDAQ
Compass Pathways PLC
$8.32
arrow_upward
+6.53%(+0.51) 1D
Nov 6, 11:04:29 AM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CMPS...
Open
$8.05
High
$8.41
Low
$7.99
Mkt. cap
1.18B
Avg. vol.
3.33M
Volume
797.67K
52-wk high
$15.87
52-wk low
$4.88
EPS
-$2.10
Beta
2.43
Shares outstanding
141.71M
No. of employees
156
Open
$8.05
High
$8.41
Low
$7.99
Mkt. cap
1.18B
Avg. vol.
3.33M
Volume
797.67K
52-wk high
$15.87
52-wk low
$4.88
EPS
-$2.10
Beta
2.43
Shares outstanding
141.71M
No. of employees
156
News stories
From web sources and news partners
Stocks Down Under
·
21 hours ago
Compass Pathways (NDQ:CMPS): Can Psychedelic Therapy Become Mainstream Medicine? If So, This Company Is Well Poised To Win!
Investing.com
·
2 days ago
Compass Pathways stock price target maintained at $21 by RBC Capital
Investing.com
·
2 days ago
Stifel reiterates Compass Pathways stock rating amid competition
Yahoo Finance
·
2 days ago
How Investors May Respond To COMPASS Pathways (CMPS) Smaller Loss And FDA Progress
Profile
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, has completed phase 3 clinical trials for treatment-resistant depression. The results showed clear benefit to participants as measured on the MADRS depression rating scale. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine.
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Wikipedia
About Compass Pathways PLC
CEO-
Employees156
FoundedJun 13, 2016
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitecompasspathways.com
Analyst ratings
Based on 9 analysts giving stock ratings to CMPS in the past 3 months
Strong buy
Buy
8
Hold
1
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for CMPS in the last 3 months.
Highest
Current $8.32
$65.00 (+681.25%)
Average
$25.22 (+203.12%)
Lowest
$10.00 (+20.19%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Paul Matteis Stifel Nicolaus | Buy | Maintained | $21.00 | +152.4% | 11/04/2026 |
Thomas Shrader BTIG | Buy | Maintained | $25.00 | +200.5% | 11/03/2026 |
Benjamin Burnett Wells Fargo | Hold | Maintained | $10.00 | +20.2% | 11/04/2026 |
Leonid Timashev RBC Capital | Buy | Maintained | $21.00 | +152.4% | 11/03/2026 |
Sumant Kulkarni Canaccord Genuity | Buy | Reiterated | $20.00 | +140.4% | 11/04/2026 |
Patrick Trucchio H.C. Wainwright | Buy | Maintained | $65.00 | +681.2% | 09/21/2026 |
Francois Brisebois LifeSci Capital | Buy | Reiterated | $24.00 | +188.5% | 09/09/2026 |
Gavin Clark-Gartner Evercore ISI | Buy | Maintained | $21.00 | +152.4% | 08/10/2026 |
Michael Okunewitch Maxim Group | Buy | Reiterated | $20.00 | +140.4% | 08/07/2026 |
Madison Elsaadi B. Riley Securities | Buy | Maintained | $22.00 | +164.4% | 08/06/2026 |
Judah Frommer Morgan Stanley | Buy | Maintained | $18.00 | +116.3% | 08/06/2026 |
Ritu Baral TD Cowen | Buy | Maintained | $29.00 | +248.6% | 08/05/2026 |
Rudy Li Wolfe Research | Buy | Maintained | $18.00 | +116.3% | 07/07/2026 |
Jay Olson Oppenheimer | Buy | Maintained | $20.00 | +140.4% | 07/07/2026 |
Jason McCarthy Maxim Group | Buy | Reiterated | $20.00 | +140.4% | 05/15/2026 |
Andrew Tsai Jefferies | Buy | Maintained | $18.00 | +116.3% | 05/14/2026 |
Last report
Nov 3, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
-$0.31 / -$0.33
+6.06%beat
arrow_upward
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | - | - | - | - |
Cost of goods sold | - | - | - | - |
Cost of revenue | - | - | - | - |
Research and development expenses | 42.82M | 24.00M | 26.59M | 21.41M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 16.05M | 16.42M | 23.20M | 32.98M |
Operating expense | 58.86M | 40.43M | 49.79M | 54.39M |
Total operating expenses | 58.86M | 40.43M | 49.79M | 54.39M |
Operating income | -58.86M | -40.43M | -49.79M | -54.39M |
Other non operating income | -37.79M | 131.40M | -205.03M | 41.34M |
EBT including unusual items | -96.61M | 91.19M | -253.46M | -10.94M |
EBT excluding unusual items | -96.61M | 91.19M | -253.46M | -10.94M |
Income tax expense | -2.73M | -11.00K | 331.00K | -1.11M |
Effective tax rate | 2.83% | -0.01% | -0.13% | 10.11% |
Other operating expenses | - | - | - | - |
Net income | -93.88M | 91.20M | -253.79M | -9.83M |
Net profit margin | - | - | - | - |
Earnings per share | -0.61 | -0.30 | -0.36 | -0.34 |
Interest and investment income | 1.31M | 2.42M | 3.74M | 3.60M |
Interest expense | -1.14M | -1.46M | -1.48M | -1.50M |
Net interest expenses | 173.00K | 954.00K | 2.26M | 2.09M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -58.86M | -40.37M | -49.74M | -54.34M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events